Product Information
VYLIBRA 28 TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1190 per EA under NDC 50102023511. Its NADAC has been published 433 times since May 9, 2018.
FDA first approved this application on Jul 7, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Afaxys Pharma, LLCNDC
50102023511
Classification
Generic
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205449FDA Approved
7/7/2016
TE Code
AB
On Market Since
7/7/2016
Price Statistics
The NADAC for VYLIBRA 28 TABLET has been published 433 times since May 9, 2018, and over the history we have for it it has declined 56.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1190 per EA |
|---|---|
| All-time high | $0.2724 (May 16, 2018) |
| All-time low | $0.1011 (Nov 20, 2024) |
| 52-week high | $0.1336 |
| 52-week low | $0.1190 |
| Median price | $0.1552 |
| Average price | $0.1782 |
| Largest weekly change | -21.9% (Nov 20, 2024) |
| Weeks tracked | 433 |
| Tracking since | May 9, 2018 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 9% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VYLIBRA 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VYLIBRA 28 TABLET, manufactured by Afaxys Pharma, LLC, is $0.1190 per EA (NDC 50102023511), effective Aug 19, 2026.
How has the price of VYLIBRA 28 TABLET changed over time?
Over the history we have for it, the NADAC for VYLIBRA 28 TABLET has declined 56.3%. It has been tracked across 433 weekly CMS publications since May 9, 2018.
What are the highest and lowest recorded NADAC prices for VYLIBRA 28 TABLET?
Since May 9, 2018, the NADAC for VYLIBRA 28 TABLET has ranged from a low of $0.1011 (Nov 20, 2024) to a high of $0.2724 (May 16, 2018), with a median of $0.1552 per EA.
Are there cheaper alternatives to VYLIBRA 28 TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-LO-ESTARYLLA TABLET, is $0.1083 per EA — about 9% below VYLIBRA 28 TABLET.
Who manufactures VYLIBRA 28 TABLET?
VYLIBRA 28 TABLET (NDC 50102023511) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.